Duobrii vs. Skyrizi

Reviewed on 12/12/2019

Are Duobrii and Skyrizi the Same Thing?

Duobrii (halobetasol propionate and tazarotene) Lotion and Skyrizi (risankizumab-rzaa) are used to treat plaque psoriasis in adults.

Duobrii Lotion is a topical (for the skin) treatment and Skyrizi is given as a subcutaneous injection.

Duobrii and Skyrizi belong to different drug classes. Duobrii is a combination of a corticosteroid and a retinoid and Skyrizi is an interleukin-23 antagonist.

Side effects of Duobrii that are different from Skyrizi include contact dermatitis, application site pain, infected hair follicles, thinning skin, skin abrasions, rash, stretch marks, and skin peeling.

Side effects of Skyrizi that are different from Duobrii include upper respiratory infections, headache, fatigue, injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth), and tinea infections (such as ringworm, athlete's foot and jock itch)

Duobrii may interact with corticosteroids taken by mouth or injection and other products used on your skin that contain corticosteroids.

Skyrizi may interact with "live" vaccines.

What Are Possible Side Effects of Duobrii?

Common side effects of Duobrii include:

  • contact dermatitis,
  • application site pain,
  • infected hair follicles,
  • thinning skin,
  • skin abrasions,
  • rash,
  • stretch marks, and
  • skin peeling

What Are Possible Side Effects of Skyrizi?

Common side effects of Skyrizi include:

  • upper respiratory infections,
  • headache,
  • fatigue,
  • injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth), and
  • tinea infections (such as ringworm, athlete's foot and jock itch)

What Is Duobrii?

Duobrii (halobetasol propionate and tazarotene) Lotion is a combination of a corticosteroid and a retinoid indicated for the topical treatment of plaque psoriasis in adults.

What Is Skyrizi?

Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

SLIDESHOW

Types of Psoriasis: Medical Pictures and Treatments See Slideshow

What Drugs Interact With Duobrii?

Duobrii Lotion may interact with corticosteroids taken by mouth or injection, or other products used on your skin that contain corticosteroids. Tell your doctor all medications and supplements you use. Duobrii Lotion is not recommended for use during pregnancy; it may harm a fetus. A negative result for pregnancy should be obtained within 2 weeks prior to Duobrii Lotion therapy, which should begin during menstruation. Females of reproductive potential are advised to use effective contraception during treatment with Duobrii Lotion. It is unknown if Duobrii passes into breast milk.

What Drugs Interact With Skyrizi?

Skyrizi may interact with "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Skyrizi; it is unknown how it would affect a fetus. It is unknown if Skyrizi passes into breast milk. Consult your doctor before breastfeeding.

How Should Duobrii Be Taken?

Apply a thin layer dose of Duobrii Lotion to the affected areas once daily.

How Should Skyrizi Be Taken?

The dose of Skyrizi is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.

QUESTION

Psoriasis causes the top layer of skin cells to become inflamed and grow too quickly and flake off. See Answer
Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References
FDA. Duobrii Product Information

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209354s000lbl.pdf

AbbVie Inc. Skyrizi Product Information.

https://www.skyrizi.com

Health Solutions From Our Sponsors